In Search of Value $EXAI
Here I am going to take a look at the valuation of $EXAI.
Here I am going to take a look at the valuation of $EXAI.
Cash = $460 million Pounds or $542 million USD
Their first drug is for A2A which is a checkpoint for cytotoxic T cells. Based on its role in many cancers, it could be a big checkpoint should it work out. It has many competitors.
Their first drug is for A2A which is a checkpoint for cytotoxic T cells. Based on its role in many cancers, it could be a big checkpoint should it work out. It has many competitors.
I would say this is worth at least $1 billion + for A2A based on its indications.
*.1 for starting phase 1
= $100 million value
*.1 for starting phase 1
= $100 million value
CDK7 is part of controlling DNA replication in the cell cycle. Its designed to work with CDK4/6 inhibitors like Ibrance. Even if it got used in 20% of Ibrance patients, it would be worth $1 billion.
*.1 for preclincal
= $100 million value
*.1 for preclincal
= $100 million value
They have over $6.5 billion in biobucks from their partnerships with BMS and Sanofit. Since only 10% of science work out, that would be $650 million value.
Put all the valuation together and you get to $1.392 billion valuation. Estimated shares outstanding are around 122.5 million. That is $11.36 per share. That makes it about -48% under valued.
I have an error here in this valuation. I set it at $460 million cash when its 560 million Pounds. That makes it $660 USD. That increases the valuation by about $120 million.
Loading suggestions...